Clinical Trials Logo
  1. Home
  2. Congenital Bleeding Disorder
  3. NCT02920398
  4. Details
NCT02920398 Clinical Trial

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

Congenital Bleeding Disorder Clinical Trial

— pathfinder™7  

Official title:
This Trial is Conducted in Europe and the United States of America. The Aim of This Trial is to Investigate Single Dose Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02920398
Other study ID # NN7088-4033
Secondary ID 2015-005327-63U1
Status Completed
Phase Phase 1
First received September 29, 2016
Last updated December 14, 2017
Start date October 4, 2016
Est. completion date April 7, 2017

Study information
Verified date December 2017
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process in patients with severe haemophilia A

Recruitment information / eligibility
Status Completed
Enrollment 21
Est. completion date April 7, 2017
Est. primary completion date April 7, 2017
Accepts healthy volunteers No
Gender Male
Age group 12 Years and older
Eligibility Inclusion Criteria:

- Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial

- Ongoing participation in pathfinder™2

- Male, age at least 12 years at the time of signing informed consent (in certain countries the lower age limit will be 18 years, according to local requirements)

Exclusion Criteria:

- FVIII inhibitors (=0.6 BU) at last visit in pathfinder™2 prior to entry in pathfinder™7

- Planned surgery during the trial

- Major surgery performed within 4 weeks prior to screening

- Previous participation in this trial. Participation is defined as signed informed consent

- Any disorder, except for conditions associated with haemophilia A, which in the investigator's opinion might jeopardise patient's safety or compliance with the protocol

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• turoctocog alfa pegol
Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.

Locations
Country Name City State
Denmark Novo Nordisk Investigational Site Århus N
France Novo Nordisk Investigational Site Bron Cedex
France Novo Nordisk Investigational Site Nantes Cedex 1
Germany Novo Nordisk Investigational Site Berlin
Germany Novo Nordisk Investigational Site Frankfurt/M.
Germany Novo Nordisk Investigational Site Homburg
Netherlands Novo Nordisk Investigational Site Groningen
Spain Novo Nordisk Investigational Site Madrid
Spain Novo Nordisk Investigational Site Málaga
United States Novo Nordisk Investigational Site Baltimore Maryland
United States Novo Nordisk Investigational Site Dayton Ohio
United States Novo Nordisk Investigational Site Iowa City Iowa
United States Novo Nordisk Investigational Site Nashville Tennessee
United States Novo Nordisk Investigational Site Torrance California

Sponsors (1)
Lead Sponsor Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

United States,  Denmark,  France,  Germany,  Netherlands,  Spain, 

Outcome
Type Measure Description Time frame Safety issue
Primary Area under the FVIII activity-time curve From 0 to 96 hours post injection
Secondary FVIII activity 30 min post administration - dose normalised to 50 U/kg From time of trial product administration to 96 hours post-dose
Secondary Area under the FVIII activity-time curve from 0 to infinity From time of trial product administration to 96 hours post-dose
Secondary Clearance in blood plasma of FVIII activity From time of trial product administration to 96 hours post-dose
Secondary Incremental recovery in blood plasma of FVIII activity From time of trial product administration to 96 hours post-dose
Secondary Terminal half-life From time of trial product administration to 96 hours post-dose
See also
  Status Clinical Trial Phase
Completed NCT00978380 - Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 Phase 3
Completed NCT02568202 - Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) N/A
Completed NCT01949792 - A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors Phase 1
Completed NCT01205724 - Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A Phase 1
Completed NCT01562587 - Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State Phase 1
Completed NCT00108797 - Trial of NovoSeven® in Haemophilia - Joint Bleeds Phase 4
Completed NCT01493778 - Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A Phase 3
Completed NCT02490787 - Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects Phase 1
Completed NCT00951405 - Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors Phase 2
Completed NCT01876745 - A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan N/A
Completed NCT00984126 - Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 Phase 3
Completed NCT01228669 - Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B Phase 1
Completed NCT01988532 - Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia N/A
Completed NCT01234545 - Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors N/A
Completed NCT01779921 - Treatment of Congenital Factor VII Deficiency N/A
Completed NCT01563471 - Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers Phase 1
Completed NCT02941354 - Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A Phase 1
Completed NCT02241694 - To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives N/A
Completed NCT01238367 - A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 Phase 1
Completed NCT01230021 - Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency Phase 3